Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 8/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.41 |
| ▸ | MMP12 | P39900 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | CASP9 | P55211 | 1/20 | 0.38 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7382605 | 1.00 | CASP1 (0.54) | CASP1ITGB3ITGA2BMMP8MMP12 | |
| SCHEMBL7383422 | 0.92 | ITGB3 (0.45) | CASP1ITGB3ITGA2BALDH1A1CASP3 | |
| SCHEMBL7376631 | 0.86 | CASP1 (0.49) | CASP1ITGB3ITGA2BMMP12MMP1 | |
| SCHEMBL7891700 | 0.83 | ALDH1A1 (0.45) | CASP1ITGB3ITGA2BALDH1A1 | |
| SCHEMBL7417602 | 0.81 | ITGB3 (0.40) | CASP1ITGB3ITGA2BALDH1A1CASP3 | |
| SCHEMBL7417598 | 0.81 | ITGB3 (0.40) | CASP1ITGB3ITGA2BALDH1A1CASP3 | |
| SCHEMBL8411016 | 0.80 | ITGB3 (0.51) | CASP1ITGB3ITGA2BALDH1A1CASP3 | |
| SCHEMBL312343 | 0.80 | ITGB3 (0.51) | CASP1ITGB3ITGA2BALDH1A1CASP3 | |
| SCHEMBL7382571 | 0.80 | ITGB3 (0.54) | ITGB3ITGA2BALDH1A1 | |
| SCHEMBL7420894 | 0.78 | ITGB3 (0.52) | ITGB3ITGA2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946502-B1 | SULFONAMIDE INTERLEUKIN-BETA CONVERTING ENZYME INHIBITORS | WARNER LAMBERT CO (US) | 2002-12-18 | — | — | EP | claimed |
| US-20020156094-A1 | Sulfonamide interleukin-1beta converting enzyme inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | claimed |
| US-6316415-B1 | INHIBITORS OF INTERLEUKIN-1.BETA. CONVERTING ENZYME THAT HAVE THE TREATMENT OF STROKE, REPERFUSION INJURY, ALZHEIMER'S DISEASE, SHIGELLOSIS, INFLAMMATORY DISEASES, SEPTIC SHOCK AND TO AN INHIBITOR OF INTERLEUKIN-1.BETA. CONVERTING ENZYME. | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-13 | — | — | US | claimed |
| EP-0946502-B1 | SULFONAMIDE INTERLEUKIN-BETA CONVERTING ENZYME INHIBITORS | WARNER LAMBERT CO (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020156094-A1 | Sulfonamide interleukin-1beta converting enzyme inhibitors | WARNER-LAMBERT COMPANY | 2002-10-24 | — | — | US | disclosed |
| US-6316415-B1 | INHIBITORS OF INTERLEUKIN-1.BETA. CONVERTING ENZYME THAT HAVE THE TREATMENT OF STROKE, REPERFUSION INJURY, ALZHEIMER'S DISEASE, SHIGELLOSIS, INFLAMMATORY DISEASES, SEPTIC SHOCK AND TO AN INHIBITOR OF INTERLEUKIN-1.BETA. CONVERTING ENZYME. | BASF AKTIENGESELLSCHAFT (DE) | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156094-A1 | Sulfonamide interleukin-1beta converting enzyme inhibitors | IL1A, IL1B, IL1R1 | CASP1 11/4885ITGB3 4109/4885ITGA2B 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.